GB2542881B - Crystal forms of ß-nicotinamide mononucleotide - Google Patents

Crystal forms of ß-nicotinamide mononucleotide Download PDF

Info

Publication number
GB2542881B
GB2542881B GB201608747A GB201608747A GB2542881B GB 2542881 B GB2542881 B GB 2542881B GB 201608747 A GB201608747 A GB 201608747A GB 201608747 A GB201608747 A GB 201608747A GB 2542881 B GB2542881 B GB 2542881B
Authority
GB
United Kingdom
Prior art keywords
crystal forms
nicotinamide mononucleotide
mononucleotide
nicotinamide
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB201608747A
Other languages
English (en)
Other versions
GB2542881A8 (en
GB201608747D0 (en
GB2542881A (en
Inventor
Carr Andrew
Fernandes Philippe
J Livingston David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metrobiotech LLC
Original Assignee
Metrobiotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metrobiotech LLC filed Critical Metrobiotech LLC
Publication of GB201608747D0 publication Critical patent/GB201608747D0/en
Publication of GB2542881A publication Critical patent/GB2542881A/en
Publication of GB2542881A8 publication Critical patent/GB2542881A8/en
Application granted granted Critical
Publication of GB2542881B publication Critical patent/GB2542881B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
GB201608747A 2015-10-02 2016-05-18 Crystal forms of ß-nicotinamide mononucleotide Active GB2542881B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562236657P 2015-10-02 2015-10-02

Publications (4)

Publication Number Publication Date
GB201608747D0 GB201608747D0 (en) 2016-06-29
GB2542881A GB2542881A (en) 2017-04-05
GB2542881A8 GB2542881A8 (en) 2017-05-10
GB2542881B true GB2542881B (en) 2020-01-01

Family

ID=56320606

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201608747A Active GB2542881B (en) 2015-10-02 2016-05-18 Crystal forms of ß-nicotinamide mononucleotide

Country Status (14)

Country Link
US (6) US10392415B2 (https=)
EP (2) EP4272746A3 (https=)
JP (4) JP2018534265A (https=)
KR (1) KR102779733B1 (https=)
CN (1) CN108697722B (https=)
AU (1) AU2016331918B2 (https=)
BR (1) BR112018006243A2 (https=)
CA (1) CA3000744C (https=)
EA (1) EA037104B1 (https=)
GB (1) GB2542881B (https=)
IL (1) IL258276B (https=)
MX (1) MX390064B (https=)
WO (1) WO2017059249A1 (https=)
ZA (1) ZA201802657B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN106470687A (zh) * 2015-12-11 2017-03-01 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的保健品中的应用及其保健品
WO2016188091A1 (zh) * 2015-12-11 2016-12-01 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物
WO2018047715A1 (ja) * 2016-09-06 2018-03-15 協和発酵バイオ株式会社 β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法
EP3538099B1 (en) 2016-11-11 2026-04-22 The Queen's University of Belfast Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
JP7136795B2 (ja) 2016-11-29 2022-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 母体の健康および／または子の健康を向上させるためのｎａｄ前駆体の使用
WO2018213715A1 (en) * 2017-05-18 2018-11-22 Elysium Health, Inc. Methods and compositions for improving sleep
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US10654883B2 (en) 2018-05-15 2020-05-19 Jumpstart Fertility Pty Ltd Inorganic salts of nicotinic acid mononucleotide as anti-aging agents
CN109674808A (zh) * 2019-01-30 2019-04-26 四川大学 β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途
CN109939120B (zh) * 2019-03-01 2020-01-31 北京慧宝源生物技术股份有限公司 含烟酰胺单核苷酸和罗汉果苷的组合物及其应用
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
CN110658224B (zh) * 2019-10-15 2022-11-22 中国中医科学院中药研究所 一种氢核磁定量分析技术测定nmn绝对含量的方法
CN112823778B (zh) * 2019-11-21 2024-06-14 百瑞全球有限公司 毛发护理组合物及其制备方法
CN113121628A (zh) * 2019-12-30 2021-07-16 尚科生物医药（上海）有限公司 一种无定型烟酰胺单核苷酸的制备方法
JP7648026B2 (ja) * 2020-03-27 2025-03-18 オリエンタル酵母工業株式会社 β－ニコチンアミドモノヌクレオチド又はその薬理学的に許容される塩からなる化合物を含む組成物、並びにその品質評価方法および酵素反応性の判定方法
EP4130250A4 (en) * 2020-03-30 2024-05-15 Oriental Yeast Co., Ltd. STABILIZER FOR STEM CELL CHROMOSOMES
FR3110836B1 (fr) * 2020-05-29 2023-06-16 Nuvamid Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence
CN111588729A (zh) * 2020-06-16 2020-08-28 无锡脑镁素生物医药科技有限公司 β-烟酰胺单核苷酸在预防脱发或促进毛发生长产品中的应用
CN112538101B (zh) * 2020-08-13 2026-02-03 常州博海威医药科技股份有限公司 一种β烟酰胺单核苷酸的新晶型及其制备方法和用途
CN112076204A (zh) * 2020-09-29 2020-12-15 深圳雾件科技有限公司 一种烟酰胺单核苷酸在运动神经元修复的应用
CN114349809A (zh) * 2020-10-13 2022-04-15 华东理工大学 β-烟酰胺单核苷酸的晶型A及其制备方法
CN116528696A (zh) * 2020-11-27 2023-08-01 未来实验室生物科学有限公司 高纯度β烟酰胺单核苷酸（NMN）及其制造方法
CN112694505A (zh) * 2020-12-30 2021-04-23 音芙医药科技(上海)有限公司 一种高密度的nmn的制备方法
US20230302033A1 (en) * 2021-04-13 2023-09-28 Animal Biosciences, Inc. Formulations of nicotinic acid derivatives and flavonoid polyphenols and uses thereof
AU2022281388A1 (en) 2021-05-27 2023-12-07 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
CN113912653B (zh) * 2021-06-04 2024-04-23 天津大学 一种提高β-烟酰胺单核苷酸结晶粉末松堆密度的方法
CN113292619B (zh) * 2021-06-18 2022-04-22 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸-异烟碱共晶体及其组合物
CN113402575B (zh) * 2021-06-18 2022-04-22 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸共晶体的方法
WO2023077503A1 (zh) * 2021-11-08 2023-05-11 邦泰生物工程(深圳)有限公司 一种提高烟酰胺单核苷酸晶体的堆密度的方法及其晶体
CN114129509B (zh) * 2021-12-03 2023-12-01 药酚享科技(北京)有限公司 一种保湿性nmn亲水凝胶剂及其制备方法
CN114214270B (zh) * 2021-12-17 2023-11-24 中国农业科学院北京畜牧兽医研究所 一种调控冷冻牛卵母细胞的发育能力的方法及其应用
CN114213486A (zh) * 2021-12-31 2022-03-22 浙江拓普药业股份有限公司 一种西兰花中烟酰胺单核苷酸的提取纯化方法
CN114540283B (zh) * 2022-01-27 2023-10-20 中国农业科学院北京畜牧兽医研究所 用于牛体外胚胎生产的高效玻璃化冷冻方法
WO2024251966A1 (en) 2023-06-07 2024-12-12 Bohan & Co As. Crystalline reduced nicotinamide mononucleotide (nmnh) and process thereof
CN121532403A (zh) * 2023-06-29 2026-02-13 株式会社钟化 结晶性复合体及其制造方法、以及组合物
CN117126213A (zh) * 2023-08-07 2023-11-28 青岛瑞思德生物科技有限公司 一种关于nmn制备的重结晶方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201389A (en) 1962-09-24 1965-08-17 Kyowa Hakko Kogyo Kk Method for preparing ribonucleoside-5'-phosphates or their salts from ribonucleosides
US3451997A (en) 1965-11-30 1969-06-24 Kyowa Hakko Kogyo Kk Monothio-phosphate ester catalysis for preparation of ribonucleoside derivatives
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4411995A (en) 1981-09-28 1983-10-25 Massachusetts Institute Of Technology Synthesis of nicotinamide cofactors
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
DK0999825T3 (da) 1997-07-29 2004-02-09 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EA200301204A1 (ru) 2001-04-30 2004-04-29 Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты)
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20040224039A1 (en) 2003-02-12 2004-11-11 Donald Brucker Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2553542A1 (en) 2003-10-31 2005-04-30 Robarts Research Institute Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad
JP2008501343A (ja) 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
AU2006218403A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JP5063878B2 (ja) 2005-08-30 2012-10-31 扶桑薬品工業株式会社 硫化水素塩を含有する消化器系疾患の予防／治療用組成物
US20080020413A1 (en) * 2006-03-29 2008-01-24 Columbia University Crystalline visfatin and methods therefor
CA2646674A1 (en) 2006-04-20 2007-11-01 Fred Hutchinson Cancer Research Center Use of chalcogenides for treating shock and other adverse conditions
US20080318892A1 (en) 2006-04-28 2008-12-25 John Geoffrey Pickering Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
EP2124985A4 (en) * 2007-01-26 2011-06-08 Univ Washington METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
CN101497638B (zh) 2008-01-30 2012-09-26 中国科学院大连化学物理研究所 一种nad+类似物及其合成和应用
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
CN101601679B (zh) 2009-03-17 2011-08-10 中国人民解放军第二军医大学 一种烟酰胺单核苷酸的应用
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
KR20110061909A (ko) * 2009-12-02 2011-06-10 삼성전자주식회사 도펀트로 도핑된 그라펜 및 이를 이용한 소자
CN102985553B (zh) 2010-04-15 2015-11-25 西特里斯药业公司 沉默调节蛋白活化剂和活化测定
JP5663576B2 (ja) 2010-07-06 2015-02-04 秀則 上西 神経突起伸長剤
PE20140011A1 (es) 2010-09-03 2014-01-31 Forma Tm Llc Compuestos y composiciones novedosos para la inhibicion de nampt
CN106243023A (zh) 2010-09-03 2016-12-21 福马Tm有限责任公司 用于抑制nampt的胍化合物和组合物
JP6038792B2 (ja) 2010-09-03 2016-12-07 フォーマ ティーエム， エルエルシー． 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
WO2012094343A1 (en) 2011-01-05 2012-07-12 Trilink Biotechnologies Chemically substituted thermosensitive probes and cofactors for hot start ligation
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
RU2017112522A (ru) 2011-05-04 2019-01-24 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
EP3345901A3 (en) 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
WO2013127268A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
ES2620612T3 (es) 2012-03-02 2017-06-29 Genentech, Inc. Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
WO2013127266A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfone and sulfoxide derivatives
JP6404717B2 (ja) 2012-03-02 2018-10-17 ジェネンテック， インコーポレイテッド アミドスピロ環状アミド及びスルホンアミド誘導体
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
WO2014059034A2 (en) * 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
CN102876759A (zh) * 2012-10-29 2013-01-16 尚科生物医药（上海）有限公司 尼克酰胺腺嘌呤二核苷酸的制备方法
WO2014074715A1 (en) 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
PL2968306T3 (pl) 2013-03-15 2024-01-29 Washington University Podawanie mononukleotydu nikotynamidu do leczenia zespołu suchego oka
US20140271355A1 (en) 2013-03-15 2014-09-18 Sabre Intellectual Property Holdings Llc Apparatus and process for focused gas phase application of biocide
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
WO2015069860A1 (en) 2013-11-06 2015-05-14 President And Fellows Of Harvard College Biological production of nad precursors and analogs
US10398701B2 (en) 2013-11-12 2019-09-03 Ortho-Nutra, Llc Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
CN105992521A (zh) 2013-11-12 2016-10-05 奥索努特拉有限责任公司 基于特咖宁的补充剂及其使用方法
EP3068364B1 (en) 2013-11-14 2021-11-03 Metro Biotech NSW Pty Ltd Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject
CN104367587B (zh) 2013-12-06 2018-06-29 中国人民解放军第二军医大学 烟酰胺单核苷酸在制备促脑缺血后神经再生药物中的应用
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
EP3116851B1 (en) 2014-03-13 2023-07-26 Salk Institute for Biological Studies Analogs of fexaramine and methods of making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
JP2017518306A (ja) 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
EP3151671A4 (en) 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
AU2015270090A1 (en) 2014-06-06 2016-12-22 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
WO2016086088A2 (en) 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
AU2015362283B2 (en) 2014-12-09 2020-07-30 Amorepacific Corporation Composition for activating longevity gene
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
CN104817604B (zh) 2015-03-16 2017-08-04 邦泰生物工程(深圳)有限公司 一种β‑烟酰胺单核苷酸的纯化方法
WO2016149672A1 (en) 2015-03-18 2016-09-22 The Regents Of The University Of California Methods of preventing and reversing stem cell aging
US20160355539A1 (en) 2015-06-04 2016-12-08 Chromadex, Inc. Selective solvent free phosphorylation
WO2016210232A1 (en) 2015-06-25 2016-12-29 N.V. Perricone Llc Niacinamide mononucleotide formulations for skin aging
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
TW201713774A (zh) 2015-08-06 2017-04-16 Kohjin Life Sciences Co Ltd 含有β-菸鹼醯胺單核苷酸的酵母萃取物及其製造方法
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3118834C (en) 2015-10-07 2024-06-11 Joel HUIZENGA Resetting biological pathways for defending against and repairing deterioration from human aging
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
US10654882B2 (en) 2015-12-21 2020-05-19 Showa Denko K.K. Nicotinamide mononucleotide derivative and salt thereof, method for producing same, topical skin preparation, cosmetic and food additive
EP3187180A1 (en) 2015-12-28 2017-07-05 Ludwig-Maximilians-Universität München Adenosylhomocysteinase binding substances for medical use
WO2017145151A1 (en) 2016-02-23 2017-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Process for preparation of nicotinamide riboside (nr) and cosmetic composition comprising (nr and a phosphate-binding agent
WO2017161165A1 (en) 2016-03-16 2017-09-21 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
MX393076B (es) 2016-04-20 2025-03-24 Chromadex Inc Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+
WO2017218580A1 (en) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
CN108026130B (zh) 2016-07-30 2021-04-02 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN108026132B (zh) 2016-07-30 2021-08-13 邦泰生物工程(深圳)有限公司 一种烟酰胺单核苷酸的纯化方法
CN107889505B (zh) 2016-07-30 2021-05-25 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN107889504B (zh) 2016-07-30 2021-07-27 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN108026535B (zh) 2016-07-30 2021-04-27 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN107922952B (zh) 2016-07-30 2021-04-27 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
WO2018047715A1 (ja) * 2016-09-06 2018-03-15 協和発酵バイオ株式会社 β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法
CN109691011B (zh) 2016-09-09 2022-06-14 日本电气株式会社 发送装置、接收装置、量子密钥分发方法和介质
US20200009170A1 (en) 2016-09-13 2020-01-09 Megumi Tanaka Sleep display agent property and method for improving sleep disorders
US10898738B2 (en) 2016-09-13 2021-01-26 Megumi Tanaka Visual function printing agent, and method for improving visual functions
EP3538099B1 (en) 2016-11-11 2026-04-22 The Queen's University of Belfast Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
CN116509885A (zh) 2016-12-21 2023-08-01 新南创新私人有限公司 增加血管密度的方法
CN106755209B (zh) 2016-12-29 2021-07-23 苏州汉酶生物技术有限公司 一种酶法制备β-烟酰胺单核苷酸的方法
US20200121704A1 (en) 2017-01-13 2020-04-23 The Regents Of The University Of Colorado, A Body Corporate Methods for treating hypertension and arterial stiffness
EP3578639A4 (en) 2017-01-31 2020-07-08 Oriental Yeast Co., Ltd. AGENT FOR ACCELERATING THE GROWTH OF STEM CELLS WITH DIFFERENTIATION POTENTIAL
JP6920071B2 (ja) 2017-02-16 2021-08-18 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ アディポネクチン分泌向上剤
US10961268B2 (en) 2017-04-05 2021-03-30 Cornell University β-nicotinate ester nucleotides and process for preparing same
EP3661601A4 (en) 2017-07-31 2020-10-07 Newsouth Innovations Pty Limited METHODS TO INCREASE FERTILITY
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US20210388018A1 (en) 2018-10-01 2021-12-16 Cornell University Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof
EP3893873A4 (en) 2018-12-10 2023-01-11 Chromadex, Inc. CRYSTALLINE FORMS OF NICOTINOYL RIBOSIDES, THEIR DERIVATIVES AND METHODS OF PREPARING THEM
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
WO2020197882A1 (en) 2019-03-22 2020-10-01 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
WO2021234009A1 (fr) 2020-05-20 2021-11-25 Nuvamid Sa Compositions cosmetiques anti-age comprenant du nmn
AU2022281388A1 (en) 2021-05-27 2023-12-07 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Beta-Nicotinamide Mononucleotide, Item No. 16411 Product information", (published 11 March 2014), Cayman Chemical, available from http://www.caymaneurope.com/pdfs/16411.pdf, (downloaded 1 November 2017) *
Biotechnology Letters, Vol. 3(7), 1981, (Berghaeuser, J. et al), pages 339-44, ISSN: 0141-5492 *
Chemical Communications (Cambridge), 1999, Vol. 8, (Lee, Jaemoon et al), pages 729-730, ISSN: 1359-7345 *
Journal of the American Chemical Society, Vol. 106(1), 1984, (Walt, David R. et al), pages 234-9, ISSN: 0002-7863 *
Nucleosides & Nucleotides, Vol. 13(5), 1994, (Liu, Rihe et al), pages 1215-16, ISSN: 0732-8311 *
Nucleosides, Nucleotides & Nucleic Acids, Vol. 24(5-7), 2005, (Dowden, James et al), pages 513-518, ISSN: 1525-7770 *
Pharmaceutical Research, Vol. 12(7), 1995, (BYRN S et al), "Pharmaceutical solids: a strategic approach to regulatory consideration", pages 945 - 954, ISSN 0724-8741 *
Polymorphism in Pharmaceutical Solids, 1999, first edition, (MARCEL DEKKER), ISBN 0-8247-0237-9 *
Synthesis, May 1981, (MIKHAILOPULO et al), "Synthesis of Glycosides of Nicotinamide and Nicotinamide Mononucleotide'', pages 388 - 389 *
Tetrahedron, Vol. 65(40), 2009, (Liu, Wujun et al), pages 8378-8383, ISSN: 0040-4020 *

Also Published As

Publication number Publication date
ZA201802657B (en) 2024-02-28
BR112018006243A2 (pt) 2018-10-16
EP3355895A4 (en) 2019-03-13
IL258276B (en) 2022-07-01
JP2021063081A (ja) 2021-04-22
KR102779733B1 (ko) 2025-03-12
US20190225641A1 (en) 2019-07-25
AU2016331918B2 (en) 2021-11-04
JP2022176979A (ja) 2022-11-30
EA201890817A1 (ru) 2018-10-31
EP4272746A2 (en) 2023-11-08
MX2018003656A (es) 2018-04-30
US11059847B2 (en) 2021-07-13
GB2542881A8 (en) 2017-05-10
US10233208B1 (en) 2019-03-19
CN108697722A (zh) 2018-10-23
EA037104B1 (ru) 2021-02-05
WO2017059249A1 (en) 2017-04-06
EP3355895A1 (en) 2018-08-08
JP2024161353A (ja) 2024-11-19
MX390064B (es) 2025-03-20
CA3000744C (en) 2024-02-13
AU2016331918A1 (en) 2018-05-10
CA3000744A1 (en) 2017-04-06
US20250171485A1 (en) 2025-05-29
EP4272746A3 (en) 2023-11-15
JP2018534265A (ja) 2018-11-22
GB201608747D0 (en) 2016-06-29
KR20180073582A (ko) 2018-07-02
GB2542881A (en) 2017-04-05
US10392415B2 (en) 2019-08-27
CN108697722B (zh) 2021-03-23
US10392416B2 (en) 2019-08-27
US20180282362A1 (en) 2018-10-04
US20190085009A1 (en) 2019-03-21
US12391721B2 (en) 2025-08-19
IL258276A (en) 2018-05-31
US20200157136A1 (en) 2020-05-21
US20220098229A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
GB2542881B (en) Crystal forms of ß-nicotinamide mononucleotide
IL259421B (en) ror - gamma modulators
IL251584B (en) Dihydropyrrolopyridines ror–gamma inhibitors
SG11201706729SA (en) Derivatives of sobetirome
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
ZA201604272B (en) Inhibitors of glutaminase
IL250391B (en) Crystalline forms of glutaminase inhibitors
DK3209673T3 (en) Mixtures of HMOs
SI3524234T1 (sl) Trdne oblike sofosbuvira
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
PT3334734T (pt) Forma c de avibactam sódico
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
IL246979A0 (en) Crystalline forms of sofosbuvir
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
ZA201706282B (en) Solid forms of menaquinols
IL255498A (en) Treatment of pruritus
IL262111A (en) Monovalent inhibitors of hutnfr1 interaction
IL253479A0 (en) Crystalline forms of efinconazole
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
GB201501636D0 (en) Pair of planes
IL249332A0 (en) Crystalline forms of sofosbuvir
GB201519083D0 (en) Crystal structure
TWM489666U (en) Structure of goggles
GB201405156D0 (en) Theory of parliament

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20200716 AND 20200722